Skip to main content

Table 2 Change in tumor expression from baseline (i.e. before atorvastatin treatment) to time of surgery (i.e. after atorvastatin treatment)

From: Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial

  Complete pairs Decreasing Unaltered Increasing P-value
ER n = 30 2 25 3 0.68
PR n = 30 3 21 6 0.19
HER2 n = 29 7 20 2 0.08
Cyclin D1 nuclear fraction n = 30 4 19 7 0.12
Cyclin D1 nuclear intensity n = 30 14 13 3 0.008*
Cyclin D1 cytoplasmic intensity n = 30 10 14 6 0.48
p27 nuclear fraction n = 33 2 22 9 0.03
p27 nuclear intensity n = 33 9 18 6 0.35
p27 cytoplasmic intensity n = 33 3 18 12 0.02
  1. P-values from Wilcoxon matched-pairs signed-ranks test.
  2. ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2.
  3. *Significant even after Bonferroni adjustment for multiple testing within the marker, P = 0.02.